VFA
ALNY icon

Virtus Fund Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Virtus Fund Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$353K Buy
+2,775
New +$349K ﹤0.01% 396

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM

Virtus Fund Advisers's ALNY Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2017: 2,775 shares worth $353K. The stake represents ﹤0.01% of the portfolio and ranks #396 among its holdings.

282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • Virtus Fund Advisers held 2,775 shares of Alnylam Pharmaceuticals worth $353K as of Q4 2017.
  • Alnylam Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #396 holding.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.